Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 13/20 | 0.43 |
| ▸ | AHCY | P23526 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540101 | 1.00 | NNMT (0.43) | NNMTAHCYADORA2BPRMT5WDR77 | |
| SCHEMBL18572585 | 0.89 | AHCY (0.52) | NNMTAHCYADORA2BPRMT5WDR77 | |
| SCHEMBL22002025 | 0.89 | AHCY (0.52) | NNMTAHCYADORA2BPRMT5WDR77 | |
| SCHEMBL9109736 | 0.89 | AHCY (0.52) | NNMTAHCYADORA2BPRMT5WDR77 | |
| SCHEMBL9469927 | 0.83 | NNMT (0.42) | NNMTPRMT5WDR77 | |
| SCHEMBL19991765 | 0.82 | NNMT (0.41) | NNMTPRMT5WDR77 | |
| SCHEMBL29540340 | 0.79 | NNMT (0.40) | NNMTPRMT5WDR77 | |
| SCHEMBL9108920 | 0.78 | NNMT (0.41) | NNMTPRMT5 | |
| SCHEMBL10248595 | 0.78 | NNMT (0.41) | NNMTPRMT5WDR77 | |
| SCHEMBL22509958 | 0.78 | PRMT5 (0.41) | NNMTPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11198699-B2 | Compounds targeting PRMT5 | ALIGOS THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200317686-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| WO-2020205867-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198699-B2 | Compounds targeting PRMT5 | PRMT5, PRMT1, PRMT6 | NNMT 656/4885AHCY 3424/4885ADORA2B 4293/4885 |
| US-20200317686-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | NNMT 656/4885AHCY 3424/4885ADORA2B 4293/4885 |
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | NNMT 656/4885AHCY 3424/4885ADORA2B 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.